Aducanumab (Aduhelm): Alzheimer's Drug Overview, Efficacy & Controversy

Aducanumab (brand name Aduhelm) received accelerated FDA approval in 2021 for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. It represents the first disease-modifying therapy targeting amyloid-beta plaques.

Mechanism of Action

A monoclonal antibody that binds aggregated amyloid-beta, promoting plaque clearance and potentially slowing neurodegeneration.

Clinical Trial Evidence

  • EMERGE trial: Showed statistically significant reduction in clinical decline at high dose.
  • ENGAGE trial: Did not meet primary endpoint; results were discordant with EMERGE.

The FDA based approval on EMERGE and a post-hoc analysis of combined data—a decision that sparked significant debate.

Dosing & Administration

Intravenous infusion every 4 weeks. Starting dose 10 mg/kg, titrated to 20 mg/kg over several months if tolerated.

Common Side Effects

  • Amyloid-related imaging abnormalities (ARIA): brain edema (ARIA-E) or microhemorrhages (ARIA-H)
  • Headache, dizziness, fatigue, confusion, nausea, falls

Controversies & Considerations

  • Mixed efficacy data; clinical significance of cognitive benefit debated.
  • High cost and need for regular MRI monitoring for ARIA.
  • Ongoing Phase 4 trials required to confirm long-term benefit.

Patients and clinicians should weigh potential modest benefits against risks, monitoring burden, and cost through shared decision-making.

Prescription Medications - Related Articles